Drug Information
Drug (ID: DG01808) and It's Reported Resistant Information
| Name |
Heliox
|
||||
|---|---|---|---|---|---|
| Synonyms |
Heliox; helium;molecular oxygen; 58933-55-4; Helium, mixed with oxygen; Helium-oxygen mixture; Helium:oxygen mixture; Compressed gas, N.O.S.; Oxygen mixture with helium; Oxygen, mixed with helium; Heliox gas; Helium oxygen gas; Heliox, hyperbaric; Helium, mixt. with oxygen; Compressed gas, N.O.S. (helium, oxygen) gas; 70356-00-2
Click to Show/Hide
|
||||
| Structure |
|
||||
| Drug Resistance Disease(s) |
Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug
(1 diseases)
[1]
|
||||
| Target | . | NOUNIPROTAC | [1] | ||
| Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
| IsoSMILES |
[He].O=O
|
||||
| InChI |
InChI=1S/He.O2/c;1-2
|
||||
| InChIKey |
GWUAFYNDGVNXRS-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Type(s) of Resistant Mechanism of This Drug
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-11: Circulatory system diseases
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) | [1] | |||
| Molecule Alteration | Up-regulation | Interaction |
||
| Resistant Disease | Ischemic cardiovascular disease [ICD-11: BA51.0] | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | HCAECs | N.A. | . | N.A. |
| In Vivo Model | Hind limb ischemia rat model | Rattus norvegicus | ||
| Experiment for Molecule Alteration |
Overexpression assay; Knockdown assay; Luciferase assay | |||
| Experiment for Drug Resistance |
CellTiter-Glo assay; dual-luciferase reporter assay | |||
| Mechanism Description | Hyperbaric oxygen boosts long noncoding RNA MALAT1 exosome secretion to suppress microRNA-92a expression in therapeutic angiogenesis. | |||
References
visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
